跳到主要內容區塊
胃腸肝膽科 Division Of Gastroenterology and Hepatology
:::快捷選單
icon網路掛號 icon看診進度 icon即時動態 衛教專區 icon服務諮詢 icon交通指南 icon健康檢查 icon常見問答 該看哪一科
:::胃腸肝膽科 > 公開資訊 > 論文發表

論文發表

引用 (6)
更新日期 2020/9/17 14:05:49
點閱 2287
台中榮民總醫院 醫學研究論文目錄
103-107年
103年SCI 期刊論文
編號
題目
Impact Factor/排名%
1
Antiviral therapy for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.(第一作者:許耀峻;通訊作者:吳俊穎;全部作者:林肇堂、何秀榮、Kao YH、Huang YT、蕭乃文、吳明賢、劉宜雅)
12.003 / 2.7%
2
The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease.(第一作者:李少武;通訊作者:李少武;全部作者:張繼森、葉宏仁、李騰裕、連漢仲、柯忠旺)
1.314 / 83.78%
3
Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells(第一作者:彭彥鈞;通訊作者:黃蘭如;全部作者:何素鵬、徐慶麟)
2.397 / 47.93%
4
Development of a Highly Sensitive Glycan Microarray for Quantifying AFP-L3 for Early Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma.(第一作者:李騰裕、吳承修;通訊作者:余永倫;全部作者:R-H C、C-J Y、W-C H、C-Y W)
3.73 / 12.5%
5
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.(第一作者:劉振驊;通訊作者:高嘉宏;全部作者:Liu CJ Huang、CF Lin JW、Dai CY、楊勝舜、Su TH...等18位)
10.732 / 4.05%
6
Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ.(第一作者:楊勝舜、張淑娟;通訊作者:李彩娟;全部作者:Chang CC、Lin CC、Chung YC)
2.272 / 27.71%
7
Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study.(第一作者:吳俊穎;通訊作者:吳肇卿、林肇堂;全部作者:何秀榮、蘇建維、李騰裕、SY Wang、CH Wu)
12.821 / 1.35%
8
Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.(第一作者:許耀峻;通訊作者:林肇堂、牟聯瑞;全部作者:吳俊穎、藍先元、張吉仰、戴啟明、曾志宏、羅錦河、彭道雄)
5.338 / 6.9%
9
Lower serum folate is associated with development and invasiveness of gastric cancer.(第一作者:李騰裕;通訊作者:吳俊穎;全部作者:EP Chiang、YT Shih、HY Lane、JT Lin)
2.547 / 45.95%
10
Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.(第一作者:楊勝舜;通訊作者:高嘉宏)
2.221 / 51.35%
11
The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonist: a nationwide cohort study.(第一作者:吳俊穎;通訊作者:陳怡如、張雲亭;全部作者:陳得源、沈瑞隆、何秀榮、陳志強、郭耿南、劉漢南)
4.302 / 17.24%
12
Interaction of omeprazole and Helicobacter pylori-induced nuclear factor-κB activation and mediators in gastric epithelial cells.(第一作者:彭彥鈞;通訊作者:何素鵬;全部作者:黃蘭如、徐慶麟、程呈章)
0.752 / 65.16%
104年SCI 期刊論文
編號
題目
Impact Factor/排名%
1
Association between antidiabetic drugs and psoriasis risk in diabetic patients: Results from a nationwide nested case-control study in Taiwan.(第一作者:吳俊穎;通訊作者:陳怡如、張雲亭;全部作者:謝政哲、沈瑞隆、劉宜雅)
5.004 / 4.91%
2
Tocilizumab-associated cutaneous reactive endotheliomatosis in a patient with rheumatoid arthritis.(第一作者:吳丞斌;通訊作者:謝佳偉;全部作者:陳得源、李博仁、楊啟順)
3.218 / 33.33%
3
Responder definition of a patient-reported outcome instrument for laryngopharyngeal reflux based on the US FDA guidance.(第一作者:連漢仲、王仲祺;通訊作者:梁文敏;全部作者:張繼森、葉宏仁、李少武、柯忠旺、許正園)
2.891 /
4
Prior statin use and the outcomes in patients with first-attack acute pancreatitis: A retrospective cohort study.(第一作者:許斯淵、蘇佩芳;通訊作者:王振宇;全部作者:張立和、李博仁)
2.3 / 23.72%
105年SCI 期刊論文
編號
題目
Impact Factor/排名%
1
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
1.78/80.3%
2
Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation.
11.055/6.58%
3
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.
1.78/80.26%
4
Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study.
5.723/9.74%
5
The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study.
3.498/35.53%
6
The suitability of the GERDyzer instrument in pH-test-proven laryngopharyngeal reflux patients.
5.723/9.74%
7
Gastric microbiota and predicted gene functions are altered after subtotal gastrectomy in patients with gastric cancer.
5.578/8.77%
8
Polymerase chain reaction-free detection of hepatitis B virus DNA using a nanostructured impedance biosensor.
6.409/3.57%
9
Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study.
14.66/2.63%
10
Effect of implementation of a coded problem list entry subsystem.
1.897/14.71%
11
Diverticular disease and additional comorbidities associated with increased risk of dementia.
3.504/34.21%

 

 

106年SCI期刊論文
編號 論文題目
Im IIi IImpact Factor/排名%
1 Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma.
(李律虹,Jen-I Hwang,Yu-Chi Cheng,吳俊穎,李少武,楊勝舜,葉宏仁,張繼森,李騰裕)
2.766/23.4%
2 The effect of proton pump inhibitors on the gastric mucosal microenvironment.
(彭彥鈞,Lan-Ru Huang,Hui-Ching Ho,張繼森,李少武, Ching-Chang Cheng, May-Ching Wen,葉宏仁, Shu-Peng Ho)
1.262/84.2%
3 On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
(黃儀倢,張繼森,彭彥鈞,葉宏仁,楊勝舜)
2.766/23.4%
4 On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy.
(黃儀倢,張繼森,彭彥鈞,葉宏仁,楊勝舜)
1.660/46.45%
5 Immediate diagnosis of ERCP-related perforation: by air, contrast medium, or eyes.
(彭彥鈞,Wai-Keung Chow)
7.204/11.25%
6 Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population- based cohort study.
(林宛姿,廖苡君,彭彥鈞,張繼森,葉宏仁,Chang CS,張崇信)
7.204/11.25%
7 The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
(李騰裕,Wu JC,Yu SH,Lin JT,Wu MS,吳俊穎)
7.360/10.31%
8 Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage.
(李騰裕,Lin CC, Chen CY, Wang TE, Lo GH, 張崇信, Chao Y)
7.360/10.31%
9 The association between cholecystectomy and colorectal neoplasm in inflammatory bowel diseases: A population-based cohort study.
(彭彥鈞,Lin CL, Sung FC)
2.766/23.4%
10 Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up.
(廖苡君,Li YC,李少武,吳俊穎,楊勝舜,葉宏仁,張崇信,李騰裕)
1.660/46.45%
11 Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
(Hung YK, Yen CL, Shiu SI, Lee SW, Chang PY,葉宏仁,李騰裕)
2.766/23.4%

 


 
107年SCI期刊論文
編號 論文題目 ImImpact Factor/排名%
1 The ultra-short virological dynamics in response to entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation.
(李騰裕,Chen CY,連漢仲,Hsu YC,楊勝舜)
ANTIVIRAL THERAPY
2 Risk of pyogenic liver abscess and endoscopic sphincterotomy: a population-based cohort study.
(彭彥鈞,Cheng-Li Lin,Fung-Chang Sung)
BMJ Open
3 Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
(Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB,李騰裕, Wu MS, Lin JT, Wong GL, Wu CY)
JOURNAL OF HEPATOLOGY
4 Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.
(李騰裕, Hsu YC,Yu SH, Lin JT, Wu MS, Wu CY)
Clinical Gastroenterology and Hepatology
5 Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
(Hsu YC, Ho HJ,李騰裕, Huang YT, Wu MS, Lin JT, Wu CY, El-Serag HB)
JOURNAL OF VIRAL HEPATITIS
6 Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
(Tsai HJ, Chuang YW,李少武,吳俊穎,葉宏仁,李騰裕)
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
7 Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study.
(彭彥鈞,Cheng-Li Lin,Wan-Yun Hsu,Wai-Keung Chow,李少武,葉宏仁,陳家昌,Chia-Hung Kao)
Frontiers in Pharmacology
8 Regulation of the regulator of G protein signaling 2 expression and cellular localization by PKA and PKC pathways in mouse granulosa cells.
(Yeh HY, Sun D,彭彥鈞, Wu YL)
Biochemical and Biophysical Research Communications
9 Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population.
(李少武,李騰裕,楊勝舜,童春芳,葉宏仁,張繼森)
Hepatobiliary & Pancreatic Diseases International
10 Proton Pump Inhibitor Use is Associated With Risk of Pancreatic Cancer: A Nested Case-Control Study.
(彭彥鈞, Lin CL,Hsu WY,Lu IT,葉宏仁,張繼森,Kao CH)
Dose-Response
11 The association between bowel obstruction and the management of cholelithiasis and cholecystitis in elderly patients: A population-based cohort study.
(彭彥鈞, Lin CL,葉宏仁,張繼森,Kao CH)
European Journal of Internal Medicine
12 The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
(李騰裕,楊勝舜)
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
13 Differences of risk factors and clinical presentations in male and female Taiwanese individuals with Barrett's esophagus.
(李少武,連漢仲,張繼森,張崇信,柯忠旺,葉宏仁)
Journal of the Chinese Medical Association
14 Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD.
(彭彥鈞, Lam-Ru Huang,Chen-Li Lin,Wan-Yun Hsu,Chi-Sen Chang,葉宏仁,Chia-Hung Kao)
GUT
15 Benefits of the Seattle biopsy protocol in the diagnosis of Barrett's esophagus in a Chinese population
(李少武,連漢仲,張繼森,林明賢,張崇信,柯忠旺)
Wrold Journal of Clinical Case

回頂端